ClinicalTrials.gg
CompletedNCT01772836Updated Jul 11, 2013

Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination

A Phase 1 interventional study of RPX7009 and Biapenem in Healthy Volunteers and Bacterial Infections, sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company). Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-07-11.

Sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Bacterial Infections with a site in Australia — 1 open to participants now, 1 under way, none of them phase 3. Bacterial Infections · Australia.

Planned enrollment
23rd of 26
30 · median 65
Started
2013
with 1 other
Phase 1
21 of 29
none open now
Registered
11th of 29
by date
Lead sponsor
3 of 29
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

Among the 29 studies in Bacterial Infections with a site in Australia, this one is the 23rd largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2013, is one of 21 in phase 1, and was the 11th registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

1 of the 29 studies in Bacterial Infections with a site in Australia is open now. Recruiting first, the newest first:

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Bacterial Infections with a site in Australia, or all of them as a file.
02

Study summary

RPX7009 (beta-lactamase inhibitor) is being studies in combination with a carbapenem biapenem to treat bacterial infections, including those due to multi-drug resistant bacteria.

Read the detailed description

The worldwide spread of resistance to antibiotics among Gram-negative bacteria, particularly members of the ESKAPE group of pathogens, has resulted in a crisis in the treatment of hospital acquired infections. In particular, the recent dissemination of a serine carbapenemase (e.g., KPC) in Enterobacteriaceae in US hospitals now poses a considerable threat to the carbapenems and other members of the beta-lactam class of antimicrobial agents.

Rempex is developing a fixed combination antibiotic of a carbapenem (RPX2003 or biapenem) plus a new beta-lactamase inhibitor (RPX7009) which has activity against serine beta-lactamases, including KPC. This Phase 1 study will assess the safety, tolerability and pharmacokinetics and pharmacodynamics of Intravenous Biapenem and RPX7009, administered alone and in combination in healthy adult subjects.

03

Conditions studied

  • Healthy Volunteers
  • Bacterial Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult males and/or females, 18 to 55 years of age
  • (BMI) ≥ 18.5 and ≤ 29.9 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive).
  • Medically healthy with clinically insignificant screening results
  • Non-tobacco/nicotine-containing product users for a minimum of 6 months prior to Day 1.
  • Sexually abstinent or use acceptable methods of

Exclusion criteria

Exclusion Criteria:

  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease.
  • History or presence of alcoholism or drug abuse within the 2 years prior to Day 1.
  • or idiosyncratic reaction to beta-lactam antibiotics (e.g. penicillins, cephalosporins, carbapenems, etc.).
  • Use of any over-the-counter (OTC) medication, including herbal products and vitamins, within the 7 days prior to Day 1. Up to 2 grams per day of acetaminophen is allowed for acute events at the discretion of the PI.
  • Plasma donation within 7 days prior to Day 1.
  • Subjects who have any abnormalities on laboratory values at screening or check-in (Day -1).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Placebo comparator
    Normal saline

    Single and multiple dose of normal saline

    Drug: Normal saline

  • Experimental
    Single dose IV of biapenem or RPX7009

    Single dose IV infusion of biapenem or RPX7009

    Drug: RPX7009 · Drug: Biapenem

  • Experimental
    Single dose of biapenem or RPX7009

    Single IV dose of biapenem or RPX7009 (for those on active drug, this will be the drug not given in the first IV treatment)

    Drug: RPX7009 · Drug: Biapenem

  • Experimental
    Biapenem and RPX7009 in combination

    Single dose followed by a multiple dose of biapenem and RPX7009 in combination

    Drug: RPX7009 · Drug: Biapenem

Interventions

  • Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)

    Also known as: (beta-lactamase inhibitor)

  • DrugBiapenem

    Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)

    Also known as: RPX2003

  • DrugNormal saline

    Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Safety from baseline to the end of the study

    Number of patients with adverse events; assessed by patient reporting, collection of vital signs, ECGs and absolute values and changes over time of hematology, chemistry and urinalysis.

    Time frame: Day 1 - Day 17

Secondary outcomes

  1. Composite of Pharmacokinetic (PK) parameters of RPX7009, biapenem & the combination following ascending single and multiple dose administration.

    Comparison will be performed between the cohorts for the plasma AUC0-t, AUC0-inf, Cmax, and Tmax. Urine PK parameters such as amount excreted and % dose excreted will be calculated from urinary excretion data.

    Time frame: Day 1 - Day 14

  2. Composite of Pharmacodynamic (PD) parameters of RPX7009, biapenem & the combination following ascending single and multiple dose administration.

    Serum for bactericidal titers (SBT) assessments will be collected on Days 1, 4, 7 and 14 (at the end-of-infusion (EOI)), and at 2, 4, and 8 hours after start of infusion.

    Time frame: Days 1-14

07

Study locations

1 site
  • CMAX
    Adelaide, South Australia 5000, Australia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2013
First posted
Jan 21, 2013
Start
Mar 2013
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Last update
Jul 11, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01772836
Responsible party
Sponsor
First posted
Jan 21, 2013
Start date
Mar 2013
Primary completion
Mar 2013
Completion
Mar 2013
Last update
Jul 11, 2013

Study contacts

Jefferey Loutit, MBChB
study director · Sponsor GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RPX7009

Start the discussion